**An experimental drug that sharply lowered levels of an inherited form of cholesterol failed to protect patients from heart attacks and strokes, leaving researchers searching for answers. Novartis’ pelacarsen reduced lipoprotein(a), or Lp(a), by 78% in the Phase 3 Horizon trial. The study included 8,322 people with elevated Lp(a) and a history of heart attack, …

The post Drug Cut Genetic Cholesterol 78%, But Heart Risks Didn’t Fall appeared first on EURweb | Black News, Culture, Entertainment & More.
http://dlvr.it/TWH2kD